BioHarvest Sciences Inc.

BHST

$1.80

-5.26%

2026-09-03 16:00:01 EDT-$0.10

Industrials

Agricultural - Commodities/Milling

NASDAQ

Active Trading

BioHarvest Sciences Inc. is a biotechnology company that operates through two segments: Products and CDMO Services. The company has developed a botanical ...

Price Action of BHST

$1.80

-5.26%-$0.10

High—

Low—

52W High-85.9%

Rel. vol—

Interval

Range1.9h

Volume—SMA5SMA10

—

BioHarvest Sciences Inc. (BHST) is a clinical and technology-driven biotechnology business centered on transforming plant enzymes/cells into standardized, bioactive ingredients. The company’s core differentiator is its proprietary Botanical SynthesisTM platform, which supports the cultivation and synthesis of active molecules found in plants. These capabilities are used to create both (1) ...BioHarvest Sciences Inc. (BHST) is a clinical and technology-driven biotechnology business centered on transforming plant enzymes/cells into standardized, bioactive ingredients. The company’s core differentiator is its proprietary Botanical SynthesisTM platform, which supports the cultivation and synthesis of active molecules found in plants. These capabilities are used to create both (1) its own consumer and therapeutic offerings and (2) contract development and manufacturing services for external partners. From a business perspective, BioHarvest operates via two segments: Products and CDMO Services. The Products segment focuses on wellness and therapeutic products built on its botanical synthesis approach. A notable example is VINIA, a dietary supplement derived from red grape cells intended to deliver the full spectrum of naturally occurring polyphenols. The CDMO Services segment broadens the company’s revenue opportunity by providing contract development and manufacturing, leveraging its platform know-how and production capabilities to serve customers that need plant-based active ingredients and formulation/manufacturing support. Geographically, BioHarvest conducts business in Israel and the United States, while its corporate base is in Vancouver, Canada. This structure supports both R&D and commercialization activities across relevant innovation and market ecosystems. Leadership is anchored by Dr. Zaki Rakib, a co-founder who has been appointed CEO (with earlier references to other executives in public materials). The company was founded in 2007 by Dr. Yochi Hagay and Dr. Zaki Rakib, reflecting its origins in combining science with nature to improve human health. In terms of cost structure and operating focus, the company’s financial indicators (as reflected in provided TTM valuation and profitability metrics) suggest an R&D and growth-oriented stage, with negative profitability measures such as negative operating/net margins and negative free cash flow figures. That pattern is typical for early-to-mid commercialization biotechs that invest heavily in development, validation, and manufacturing scale-up. Product and manufacturing execution are supported by its platform, which can reduce uncertainty in sourcing standardized botanical actives and enable repeatable production. The company’s market positioning therefore depends on (a) continued validation of bioactive outcomes, (b) scaling production efficiently for both its own products and customer programs, and (c) maintaining regulatory and quality standards for botanical-derived ingredients. Overall, BHST’s “wishes” and strategic intent implied by its platform and service model are to expand adoption of plant-based synthesized molecules through validated products and to grow recurring CDMO-type engagements—aiming to convert platform IP and production capability into diversified revenue streams while building longer-term commercial traction.ExpandCollapse

Founded

2007

Employees

CEO

Zaki Rakib

Full Name

BioHarvest Sciences Inc.

Sector

Industrials

Industry

Agricultural - Commodities/Milling

ROE

-58.30%

Market Cap

$0.03B

Current Ratio

2.24

WACC

13.34%

ROIC

-28.09%

Contact Information

https://www.bioharvest.com

(604) 622-1186

1140-625 Howe Street, Vancouver, BC V6C 2T6

Key Metrics of BHST

Snapshot

Latest / TTM · 6 periods

Market Cap

$31.19M

ROCE

-19.4%

EV / EBITDA

-4.46x

-5.5% YoY

FCF Yield

-35.1%

-25.1% YoY

Cash Conversion Cycle

119.0d

Current Ratio

2.24

Quick take

TTM —

Positive CCC

Financial Highlights of BHST

Profitability trend

Latest / TTM · 6 periods

Gross Margin

59.0%

Net Margin

-31.2%

P/E Ratio

-3.33x

n/a

Debt / Equity

0.89

n/a

Current Ratio

2.24

Dividend Yield

0.0%

Understanding

TTM —

Interest coverage is weak

Calendar of BHST

Upcoming

Sep 30, 2026In 26 days
Q3 FY2026 · Estimated results
Est. EPS $-0.14 · Revenue $9.31M · 2 analysts
Dec 30, 2026
Q4 FY2026 · Estimated results
Est. EPS $-0.12 · Revenue $10.77M · 3 analysts
Dec 31, 2026
FY2026 · Estimated annual results
Est. EPS $-0.53 · Revenue $37.42M · 3 analysts
Mar 30, 2027
Q1 FY2027 · Estimated results
Est. EPS $-0.12 · Revenue $10.21M · 1 analysts

Recent history

Jun 30, 2026
Q2 FY2026 · Results reported
EPS $-0.16 · Revenue $8.84M
Mar 31, 2026
Q1 FY2026 · Results reported
EPS $-0.12 · Revenue $8.51M
Dec 31, 2025
FY2025 · Annual results
EPS $-0.60 · Revenue $34.51M
Sep 30, 2025
Q3 FY2025 · Results reported
EPS $-0.14 · Revenue $9.07M
Jun 30, 2025
Q2 FY2025 · Results reported
EPS $-0.24 · Revenue $8.52M
Mar 31, 2025
Q1 FY2025 · Results reported
EPS $-0.13 · Revenue $7.86M

Financial Statements of BHST

5Y Trend (Revenue, Earnings, FCF)

Metric	Latest	YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.	QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).	$34.5M	+37.0%	+3.9%
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.	$-11.1M	+13.8%	-40.7%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.	+59.3%	+7.2%	-2.9%
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).	-16.2%	+41.8%	-31.6%
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.	-32.3%	+37.1%	-35.4%
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.	$-9.6M	-0.7%	-53.6%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.	-27.8%	+26.5%	-47.9%
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.	55.4%	-94.7%	+24.5%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.	3.97x	+620.4%	-24.2%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.	$47.7M	+90.7%	-2.2%

Actual vs Estimate

A Dec 31Q Sep 30

Metric	Annual (A vs E)	Annual Surprise	Quarter (A vs E)	Quarter Surprise
EPS Surprise	-0.60 vs -0.62	+2.8%	-0.16 vs -0.14	-16.4%
Revenue Surprise	$34.5M vs $34.7M	-0.5%	$8.8M vs $9.3M	-5.0%

Earnings Call Transcript of BHST

1 transcript segments

Q2 2026

Unknown Speaker

Operator: Good morning and welcome to the BioHarvest Sciences Second Quarter 2026 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. I will now hand the call over to Dory Kurowski of LifeSci Advisors. Please go ahead. Dory Kurowski: Greetings, and welcome to the BioHarvest Sciences Second Quarter 2026 Financial Results Conference Call. With us on the call this morning is Dr. Zaki Rakib, Chairman and Chief Executive Officer. Before we begin, I'd like to remind you that management will be making projections and forward-looking statements on the call today regarding future events. Any statements that are not historical facts are forward-looking statements. These statements are made pursuant to and within the meaning of the safe harbor provision of the Private Securities Litigation Reform Act of 1995. We encourage you to review BioHarvest Sciences' SEC filings, including the company's most recent Form 6-K, which identify risks and uncertainties that may cause future actual results or events to differ materially. These filings can be found on the company website as well as the SEC's website at www.sec.gov. Please note that the forward-looking statements made during today's call speak only to the date they are made, and BioHarvest Sciences undertakes no obligation to update them. And with that, I would like to turn the call over to Dr. Zaki Rakib, Chief Executive Officer of BioHarvest. Please go ahead. Operator: Hello, Dr. Zaki. Just a reminder to unmute, please. Zaki Rakib: Yes, you can hear me? Should I start from the beginning? Did you hear everything? Operator: Yes, please. Thank you. Zaki Rakib: Okay. Sorry, my apologies. Thank you, Dory, and thank you all for joining us this morning. This morning, we proudly announced our first-ever CDMO manufacturing and supply agreement, another validating deal that shows the value of our programmable plant cell biology, which yields highly consistent, bioavailable and patent protected precision botanics. These are non-GMO compounds possessing enhanced potency and purity compared to the original plant. Our AI-driven development and industrial scale bioreactors are a revolution in plant cell culture production at mass scale. This morning's announcement relates to our program that we have with a UAE-based customer for a global luxury rare fragrance. I'll talk more about this exciting announcement and what it means to BioHarvest after you hear the prerecorded review of the financials that includes a more detailed summary of our numbers for this quarter. Please note that our CFO, Bar Dichter, has prerecorded the financial summary, but for happy family-related circumstances will not be joining the call today. Our company's Controller, Roi Atsaraf, will be on the call, and if necessary, he will follow up with any unaddressed financial questions on the call. Operator? Bar Dichter: Thank you, Zaki. Good morning, everyone. I will provide you with a summary of …

Leadership Team of BHST

8 executives

Name	Title	Compensation	Gender	Year Born	Status
Zaki Rakib	Co-Founder, CEO, Executive Chairman & President	USD 499,200	—	1959	Active
Yoheved Hagay	Co-Founder & CTO	USD 349,567	—	1958	Active
Ilana Belzer	Chief Operating Officer	USD 315,197	—	1960	Active
Jared Turner	Chief Sales Officer	USD 298,000	—	—	Active
Malkit Azachi	Vice President of Research & Development	USD 214,339	—	—	Active
Michal Abargel Sapir	Vice President of Regulatory Affairs	USD 185,233	Female	—	Active
Bar Dichter	Chief Financial Officer	USD 181,110	Female	—	Active
David K. Ryan	Vice President of Investor Relations & Secretary	USD 42,781	Male	1967	Active

Recent News of BHST

Seeking Alpha8/11/2026Neutral

BioHarvest Sciences Inc. (BHST) Q2 2026 Earnings Call Transcript

MarketBeat8/11/2026Neutral

BioHarvest Sciences Q2 Earnings Call Highlights

BioHarvest Sciences NASDAQ: BHST reported second-quarter 2026 revenue of $8.8 million, up 3.8% from $8.5 million a year earlier, while highlighting its first manufacturing and supply agreement within its contract development and manufacturing organization, or CDMO, business.

Proactive Investors8/11/2026Neutral

BioHarvest posts higher Q2 revenue, secures manufacturing deal for premium fragrance compound

BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) reported higher second-quarter revenue as the plant-based molecule developer shifted spending toward manufacturing capacity. Revenue for the quarter was $8.8 million, up 3.8% from a year earlier.

Zacks Investment Research8/11/2026Neutral

BioHarvest Sciences Inc. (BHST) Reports Q2 Loss, Lags Revenue Estimates

BioHarvest Sciences Inc. (BHST) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.15 per share a year ago.

Newsfile Corp8/11/2026Neutral

BioHarvest Reports Second Quarter 2026 Financial Results and Provides Business Update

Secured first ever CDMO Manufacturing Agreement supporting planned 20-ton commercial production program over two years for rare botanical fragrance, that BioHarvest expects to drive profitable growth trajectory for CDMO business Reports $8.8 million in Q2 revenue, up 3.8% from Q2 2025 Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - August 11, 2026) - BioHarvest Sciences Inc (NASDAQ: BHST) (FSE: 8MV0), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced results from the second quarter and six months of 2026. Dr. Zaki Rakib, Chief Executive Officer of BioHarvest, stated, "We are extremely pleased to have announced a manufacturing agreement this morning with our UAE-based fragrance customer that secures commitment to produce a fragrance ingredient that is widely regarded as one of the most valuable fragrance raw materials in the world.

Historical Employee Count of BHST

Current

Minimum

Maximum

Recent Filings

Report Date	Employees	Form Type	Filing Date	SEC Filing
Dec 31, 2025	0	40-F	Mar 31, 2026	View
Dec 31, 2024	0	40-F	Mar 31, 2025	View

Related stocksAgricultural Inputs

Browse all US stocks →

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

BioHarvest Sciences Inc.